IO102-IO103 plus Keytruda improved median PFS by 8.4 months over Keytruda alone in advanced melanoma patients. The combination therapy showed a significant PFS benefit in PD-L1–negative patients, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results